Prostate Cancer: A Review
The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.
Abstract
Importance: Prostate cancer is the most common nonskin cancer in men in the US, with an estimated 299 010 new cases and 35 250 deaths in 2024. Prostate cancer is the second most common cancer in men worldwide, with 1 466 680 new cases and 396 792 deaths in 2022. Observations: The most common type of prostate cancer is adenocarcinoma (≥99%), and the median age at diagnosis is 67 years. More than 50% of prostate cancer risk is attributable to genetic factors; older age and Black race (annual incidence rate, 173.0 cases per 100 000 Black men vs 97.1 cases per 100 000 White men) are also strong risk factors. Recent guidelines encourage shared decision-making for prostate-specific antigen (PSA) screening. At diagnosis, approximately 75% of patients have cancer localized to the prostate, which is associated with a 5-year survival rate of nearly 100%. Based on risk stratification that incorporates life expectancy, tumor grade (Gleason score), tumor size, and PSA level, one-third of patients with localized prostate cancer are appropriate for active surveillance with serial PSA measurements, prostate biopsies, or magnetic resonance imaging, and initiation of treatment if the Gleason score or tumor stage increases. For patients with higher-risk disease, radiation therapy or radical prostatectomy are reasonable options; treatment decision-making should include consideration of adverse events and comorbidities. Despite definitive therapy, 2% to 56% of men with localized disease develop distant metastases, depending on tumor risk factors. At presentation, approximately 14% of patients have metastases to regional lymph nodes. An additional 10% of men have distant metastases that are associated with a 5-year survival rate of 37%. Treatment of metastatic prostate cancer primarily relies on androgen deprivation therapy, most commonly through medical castration with gonadotropin-releasing hormone agonists. For patients with newly diagnosed metastatic prostate cancer, the addition of androgen receptor pathway inhibitors (eg, darolutamide, abiraterone) improves survival. Use of abiraterone improved the median overall survival from 36.5 months to 53.3 months (hazard ratio, 0.66 [95% CI, 0.56-0.78]) compared with medical castration alone. Chemotherapy (docetaxel) may be considered, especially for patients with more extensive disease. Conclusions and Relevance: Approximately 1.5 million new cases of prostate cancer are diagnosed annually worldwide. Approximately 75% of patients present with cancer localized to the prostate, which is associated with a 5-year survival rate of nearly 100%. Management includes active surveillance, prostatectomy, or radiation therapy, depending on risk of progression. Approximately 10% of patients present with metastatic prostate cancer, which has a 5-year survival rate of 37%. First-line therapies for metastatic prostate cancer include androgen deprivation and novel androgen receptor pathway inhibitors, and chemotherapy for appropriate patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024) · CA: a cancer journal for clinicians · doi:10.3322/caac.21834 · Cited by 27,064
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
Self-citationAlpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028
Mortality Results from a Randomized Prostate-Cancer Screening Trial
Andriole, G. L., Crawford, E. D., Grubb, R. L., Buys, S. S., Chia, D., Church, T. R., Fouad, M. N., Gelmann, E. P., Kvale, P. A., Reding, D. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810696 · Cited by 2,906
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Sweeney, C. J., Chen, Y.-H., Carducci, M., Liu, G., Jarrard, D. F., Eisenberger, M., Wong, Y.-N., Hahn, N., Kohli, M., Cooney, M. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503747 · Cited by 2,896
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Sartor, O., de Bono, J., Chi, K. N., Fizazi, K., Herrmann, K., Rahbar, K., Tagawa, S. T., Nordquist, L. T., Vaishampayan, N., El-Haddad, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107322 · Cited by 2,864
Mottet, N., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Cumberbatch, M. G., De Santis, M., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.09.042 · Cited by 2,802
Roach, M., Hanks, G., Thames, H., Schellhammer, P., Shipley, W. U., Sokol, G. H., & Sandler, H. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.04.029 · Cited by 2,749
Olaparib for Metastatic Castration-Resistant Prostate Cancer
de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911440 · Cited by 2,323
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Fizazi, K., Tran, N., Fein, L., Matsubara, N., Rodriguez-Antolin, A., Alekseev, B. Y., Özgüroğlu, M., Ye, D., Feyerabend, S., Protheroe, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704174 · Cited by 2,308
Quality of Life and Satisfaction with Outcome among Prostate-Cancer Survivors
Sanda, M. G., Dunn, R. L., Michalski, J., Sandler, H. M., Northouse, L., Hembroff, L., Lin, X., Greenfield, T. K., Litwin, M. S., Saigal, C. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074311 · Cited by 2,253
James, N. D., Sydes, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Spears, M. R., Ritchie, A. W. S., Parker, C. C., Russell, J. M., Attard, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01037-5 · Cited by 1,978
Abiraterone for prostate cancer not previously treated with hormone therapy
James, N. D., de Bono, J. S., Spears, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Ritchie, A. W. S., Amos, C. L., Gilson, C., Jones, R. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702900 · Cited by 1,801
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
Pritchard, C. C., Mateo, J., Walsh, M. F., De Sarkar, N., Abida, W., Beltran, H., Garofalo, A., Gulati, R., Carreira, S., Eeles, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603144 · Cited by 1,680
Self-citationApalutamide for Metastatic, Castration-Sensitive Prostate Cancer
Chi, K. N., Agarwal, N., Bjartell, A., Chung, B. H., Pereira de Santana Gomes, A. J., Given, R., Juárez Soto, Á., Merseburger, A. S., Özgüroğlu, M., Uemura, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903307 · Cited by 1,564
The clinician's guide to prevention and treatment of osteoporosis
LeBoff, M. S., Greenspan, S. L., Insogna, K. L., Lewiecki, E. M., Saag, K. G., Singer, A. J., & Siris, E. S. (2022) · Osteoporosis International · doi:10.1007/s00198-021-05900-y · Cited by 1,487
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Keating, N. L., O'Malley, A. J., & Smith, M. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2497 · Cited by 1,455
Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force, Grossman, D. C., Curry, S. J., Owens, D. K., Bibbins-Domingo, K., Caughey, A. B., Davidson, K. W., Doubeni, C. A., Ebell, M., Epling, J. W., et al. (2018) · JAMA · doi:10.1001/jama.2018.3710 · Cited by 1,436
Montgomery, R. B., Mostaghel, E. A., Vessella, R., Hess, D. L., Kalhorn, T. F., Higano, C. S., True, L. D., & Nelson, P. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0249 · Cited by 1,419
Risk of Fracture after Androgen Deprivation for Prostate Cancer
Shahinian, V. B., Kuo, Y.-F., Freeman, J. L., & Goodwin, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041943 · Cited by 1,375
A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score
Epstein, J. I., Zelefsky, M. J., Sjoberg, D. D., Nelson, J. B., Egevad, L., Magi-Galluzzi, C., Vickers, A. J., Parwani, A. V., Reuter, V. E., Fine, S. W., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.06.046 · Cited by 1,374
Ryan, C. J., Smith, M. R., Fizazi, K., Saad, F., Mulders, P. F. A., Sternberg, C. N., Miller, K., Logothetis, C. J., Shore, N. D., Small, E. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71205-7 · Cited by 1,369
Huggins, C., & Hodges, C. V. (1972) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.22.4.232 · Cited by 1,320
Berthold, D. R., Pond, G. R., Soban, F., de Wit, R., Eisenberger, M., & Tannock, I. F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4008 · Cited by 1,145
Kyriakopoulos, C. E., Chen, Y.-H., Carducci, M. A., Liu, G., Jarrard, D. F., Hahn, N. M., Shevrin, D. H., Dreicer, R., Hussain, M., Eisenberger, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3657 · Cited by 1,104
Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer
Resnick, M. J., Koyama, T., Fan, K.-H., Albertsen, P. C., Goodman, M., Hamilton, A. S., Hoffman, R. M., Potosky, A. L., Stanford, J. L., Stroup, A. M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209978 · Cited by 979
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Parker, C., Castro, E., Fizazi, K., Heidenreich, A., Ost, P., Procopio, G., Tombal, B., & Gillessen, S. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.011 · Cited by 977
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer
Smith, M. R., Hussain, M., Saad, F., Fizazi, K., Sternberg, C. N., Crawford, E. D., Kopyltsov, E., Park, C. H., Alekseev, B., Montesa-Pino, Á., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2119115 · Cited by 977
Overdiagnosis and Overtreatment of Prostate Cancer
Loeb, S., Bjurlin, M. A., Nicholson, J., Tammela, T. L., Penson, D. F., Carter, H. B., Carroll, P., & Etzioni, R. (2014) · European Urology · doi:10.1016/j.eururo.2013.12.062 · Cited by 964
Familial Risk and Heritability of Cancer Among Twins in Nordic Countries
Mucci, L. A., Hjelmborg, J. B., Harris, J. R., Czene, K., Havelick, D. J., Scheike, T., Graff, R. E., Holst, K., Möller, S., Unger, R. H., et al. (2016) · JAMA · doi:10.1001/jama.2015.17703 · Cited by 938
Messing, E. M., Manola, J., Yao, J., Kiernan, M., Crawford, D., Wilding, G., di'SantAgnese, P. A., & Trump, D. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70700-8 · Cited by 893
Fizazi, K., Foulon, S., Carles, J., Roubaud, G., McDermott, R., Fléchon, A., Tombal, B., Supiot, S., Berthold, D., Ronchin, P., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00367-1 · Cited by 847
Fizazi, K., Tran, N., Fein, L., Matsubara, N., Rodriguez-Antolin, A., Alekseev, B. Y., Özgüroğlu, M., Ye, D., Feyerabend, S., Protheroe, A., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30082-8 · Cited by 833
Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them
Nguyen, P. L., Alibhai, S. M. H., Basaria, S., D’Amico, A. V., Kantoff, P. W., Keating, N. L., Penson, D. F., Rosario, D. J., Tombal, B., & Smith, M. R. (2015) · European Urology · doi:10.1016/j.eururo.2014.07.010 · Cited by 831
Oesterling, J. E. (1993) · JAMA · doi:10.1001/jama.1993.03510070082041 · Cited by 807
Gravis, G., Fizazi, K., Joly, F., Oudard, S., Priou, F., Esterni, B., Latorzeff, I., Delva, R., Krakowski, I., Laguerre, B., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70560-0 · Cited by 744
A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer
Hugosson, J., Roobol, M. J., Månsson, M., Tammela, T. L. J., Zappa, M., Nelen, V., Kwiatkowski, M., Lujan, M., Carlsson, S. V., Talala, K. M., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.02.009 · Cited by 698
Changes in body composition during androgen deprivation therapy for prostate cancer
Smith, M. R., Finkelstein, J. S., McGovern, F. J., Zietman, A. L., Fallon, M. A., Schoenfeld, D. A., & Kantoff, P. W. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8299 · Cited by 697
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
de Wit, R., de Bono, J., Sternberg, C. N., Fizazi, K., Tombal, B., Wülfing, C., Kramer, G., Eymard, J.-C., Bamias, A., Carles, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911206 · Cited by 663
Ilic, D., Djulbegovic, M., Jung, J. H., Hwang, E. C., Zhou, Q., Cleves, A., Agoritsas, T., & Dahm, P. (2018) · BMJ · doi:10.1136/bmj.k3519 · Cited by 641
Prevalence of incidental prostate cancer: A systematic review of autopsy studies
Bell, K., Mar, C. D., Wright, R. G., Dickinson, J. A., & Glasziou, P. (2015) · International Journal of Cancer · doi:10.1002/ijc.29538 · Cited by 599
Agarwal, N., Azad, A. A., Carles, J., Fay, A. P., Matsubara, N., Heinrich, D., Szczylik, C., De Giorgi, U., Young Joung, J., Fong, P. C. C., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01055-3 · Cited by 538
Interpretation and use of FRAX in clinical practice
Task Force of the FRAX Initiative, Kanis, J. A., Hans, D., Cooper, C., Baim, S., Bilezikian, J. P., Binkley, N., Cauley, J. A., Compston, J. E., Dawson-Hughes, B., et al. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1713-z · Cited by 532
Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations
Jemal, A., Fedewa, S. A., Ma, J., Siegel, R., Lin, C. C., Brawley, O., & Ward, E. M. (2015) · JAMA · doi:10.1001/jama.2015.14905 · Cited by 469
Taitt, H. E. (2018) · American Journal of Men's Health · doi:10.1177/1557988318798279 · Cited by 463
Rucaparib or Physician’s Choice in Metastatic Prostate Cancer
Fizazi, K., Piulats, J. M., Reaume, M. N., Ostler, P., McDermott, R., Gingerich, J. R., Pintus, E., Sridhar, S. S., Bambury, R. M., Emmenegger, U., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2214676 · Cited by 449
Quality-of-Life Effects of Prostate-Specific Antigen Screening
Heijnsdijk, E. A. M., Wever, E. M., Auvinen, A., Hugosson, J., Ciatto, S., Nelen, V., Kwiatkowski, M., Villers, A., Páez, A., Moss, S. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201637 · Cited by 427
Beer, T. M., Armstrong, A. J., Rathkopf, D., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Evans, C. P., Kim, C.-S., Kimura, G., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.07.032 · Cited by 424
Nørgaard, M., Jensen, A. Ø., Jacobsen, J. B., Cetin, K., Fryzek, J. P., & Sørensen, H. T. (2010) · Journal of Urology · doi:10.1016/j.juro.2010.03.034 · Cited by 406
MRI-Targeted or Standard Biopsy in Prostate Cancer Screening
Eklund, M., Jäderling, F., Discacciati, A., Bergman, M., Annerstedt, M., Aly, M., Glaessgen, A., Carlsson, S., Grönberg, H., & Nordström, T. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100852 · Cited by 400
Seidenfeld, J., Samson, D. J., Hasselblad, V., Aronson, N., Albertsen, P. C., Bennett, C. L., & Wilt, T. J. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-7-200004040-00009 · Cited by 398
Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening
Wei, J. T., Barocas, D., Carlsson, S., Coakley, F., Eggener, S., Etzioni, R., Fine, S. W., Han, M., Kim, S. K., Kirkby, E., et al. (2023) · Journal of Urology · doi:10.1097/ju.0000000000003491 · Cited by 391
Self-citationAttard, G., Murphy, L., Clarke, N. W., Cross, W., Jones, R. J., Parker, C. C., Gillessen, S., Cook, A., Brawley, C., Amos, C. L., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02437-5 · Cited by 386
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
Chi, K. N., Rathkopf, D., Smith, M. R., Efstathiou, E., Attard, G., Olmos, D., Lee, J. Y., Small, E. J., Pereira de Santana Gomes, A. J., Roubaud, G., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01649 · Cited by 355
Saad, F., Clarke, N. W., Oya, M., Shore, N., Procopio, G., Guedes, J. D., Arslan, C., Mehra, N., Parnis, F., Brown, E., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00382-0 · Cited by 326
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer
Freedland, S. J., de Almeida Luz, M., De Giorgi, U., Gleave, M., Gotto, G. T., Pieczonka, C. M., Haas, G. P., Kim, C.-S., Ramirez-Backhaus, M., Rannikko, A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303974 · Cited by 319
Valle, L. F., Lehrer, E. J., Markovic, D., Elashoff, D., Levin-Epstein, R., Karnes, R. J., Reiter, R. E., Rettig, M., Calais, J., Nickols, N. G., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.11.010 · Cited by 316
Attard, G., Murphy, L. R., Clarke, N. W., Cross, W. R., Jones, R. J., Parker, C. C., Gillessen, S., Cook, A. D., Brawley, C., Amos, C. L., et al. (2022) · BORIS (University Library Bern) · doi:10.48350/164184 · Cited by 303
Hoffman, K. E., Penson, D. F., Zhao, Z., Huang, L.-C., Conwill, R., Laviana, A. A., Joyce, D. D., Luckenbaugh, A. N., Goodman, M., Hamilton, A. S., et al. (2020) · JAMA · doi:10.1001/jama.2019.20675 · Cited by 298
Schrader, A. J., Boegemann, M., Ohlmann, C.-H., Schnoeller, T. J., Krabbe, L.-M., Hajili, T., Jentzmik, F., Stoeckle, M., Schrader, M., Herrmann, E., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.06.042 · Cited by 284
Epstein, J. I., Amin, M. B., Fine, S. W., Algaba, F., Aron, M., Baydar, D. E., Beltran, A. L., Brimo, F., Cheville, J. C., Colecchia, M., et al. (2021) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2020-0015-ra · Cited by 280
Naji, L., Randhawa, H., Sohani, Z., Dennis, B., Lautenbach, D., Kavanagh, O., Bawor, M., Banfield, L., & Profetto, J. (2018) · The Annals of Family Medicine · doi:10.1370/afm.2205 · Cited by 271
Schröder, F. H., Hugosson, J., Carlsson, S., Tammela, T., Määttänen, L., Auvinen, A., Kwiatkowski, M., Recker, F., & Roobol, M. J. (2012) · European Urology · doi:10.1016/j.eururo.2012.05.068 · Cited by 270
Jahn, J. L., Giovannucci, E. L., & Stampfer, M. J. (2015) · International Journal of Cancer · doi:10.1002/ijc.29408 · Cited by 268
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications
Aurilio, G., Cimadamore, A., Mazzucchelli, R., Lopez-Beltran, A., Verri, E., Scarpelli, M., Massari, F., Cheng, L., Santoni, M., & Montironi, R. (2020) · Cells · doi:10.3390/cells9122653 · Cited by 258
Pinsky, P. F., Prorok, P. C., Yu, K., Kramer, B. S., Black, A., Gohagan, J. K., Crawford, E. D., Grubb, R. L., & Andriole, G. L. (2017) · Cancer · doi:10.1002/cncr.30474 · Cited by 256
Hussain, M., Tombal, B., Saad, F., Fizazi, K., Sternberg, C. N., Crawford, E. D., Shore, N., Kopyltsov, E., Kalebasty, A. R., Bögemann, M., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00041 · Cited by 229
Bianchini, D., Lorente, D., Rodriguez-Vida, A., Omlin, A., Pezaro, C., Ferraldeschi, R., Zivi, A., Attard, G., Chowdhury, S., & de Bono, J. S. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2013.08.020 · Cited by 204
Histopathology of Prostate Cancer
Humphrey, P. A. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030411 · Cited by 204
Sweeney, C. J., Martin, A. J., Stockler, M. R., Begbie, S., Cheung, L., Chi, K. N., Chowdhury, S., Frydenberg, M., Horvath, L. G., Joshua, A. M., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00063-3 · Cited by 204
Zumsteg, Z. S., Spratt, D. E., Romesser, P. B., Pei, X., Zhang, Z., Polkinghorn, W., McBride, S., Kollmeier, M., Yamada, Y., & Zelefsky, M. J. (2015) · European Urology · doi:10.1016/j.eururo.2014.09.028 · Cited by 200
Mian, B. M., Feustel, P. J., Aziz, A., Kaufman, R. P., Bernstein, A., Avulova, S., & Fisher, H. A. �. (2023) · The Journal of Urology · doi:10.1097/ju.0000000000003788 · Cited by 171
Armstrong, A. J., Lin, P., Tombal, B., Saad, F., Higano, C. S., Joshua, A. M., Parli, T., Rosbrook, B., van Os, S., & Beer, T. M. (2020) · European Urology · doi:10.1016/j.eururo.2020.04.061 · Cited by 168
A nomogram predicting long‐term biochemical recurrence after radical prostatectomy
Suardi, N. R., Porter, C. R., Reuther, A. M., Walz, J. C., Kodama, K., Gibbons, R. P., Correa, R. J., Montorsi, F., Graefen, M., Huland, H., et al. (2008) · Cancer · doi:10.1002/cncr.23293 · Cited by 157
Inflammation in Prostate Biopsies of Men without Prostatic Malignancy or Clinical Prostatitis
Schatteman, P. H. F., Hoekx, L., Wyndaele, J., Jeuris, W., & Marck, E. V. (2000) · European Urology · doi:10.1159/000020161 · Cited by 154
Lawton, C. A., Lin, X., Hanks, G. E., Lepor, H., Grignon, D. J., Brereton, H. D., Bedi, M., Rosenthal, S. A., Zeitzer, K. L., Venkatesan, V., et al. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.02.004 · Cited by 154
Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality
Martin, R. M., Turner, E. L., Young, G., Metcalfe, C., Walsh, E. I., Lane, J. A., Sterne, J. A. C., Noble, S., Holding, P., Ben‐Shlomo, Y., et al. (2024) · JAMA · doi:10.1001/jama.2024.4011 · Cited by 125
Fizazi, K., & Gillessen, S. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.02.015 · Cited by 119
Prostate Cancer Racial Disparities: A Systematic Review by the Prostate Cancer Foundation Panel
Mahal, B. A. V., Gerke, T. A., Awasthi, S., Soule, H. R., Simons, J. W., Miyahira, A. K., Halabi, S., George, D. J., Platz, E. A., Mucci, L. A., et al. (2021) · European Urology Oncology · doi:10.1016/j.euo.2021.07.006 · Cited by 107
Functional Outcomes After Localized Prostate Cancer Treatment
Awamlh, B. A. H. A., Wallis, C. J. D., Penson, D. F., Huang, L., Zhao, Z., Conwill, R. M., Talwar, R., Morgans, A. K., Goodman, M. G., Hamilton, A. S., et al. (2024) · JAMA · doi:10.1001/jama.2023.26491 · Cited by 107
Ola Bratt, A., Drevin, L., Akre, O., Garmo, H., & Stattin, P. E. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw110 · Cited by 100
Petersen, L. J., & Zacho, H. D. (2020) · Cancer Imaging · doi:10.1186/s40644-020-0290-9 · Cited by 100
Mahal, B. A., Aizer, A. A., Ziehr, D. R., Hyatt, A. S., Sammon, J. D., Schmid, M., Choueiri, T. K., Hu, J. C., Sweeney, C. J., Beard, C. J., et al. (2014) · Urology · doi:10.1016/j.urology.2014.05.009 · Cited by 96
Satapathy, S., Singh, H., Kumar, R., & Mittal, B. R. (2020) · American Journal of Roentgenology · doi:10.2214/ajr.20.23912 · Cited by 95
Pozdnyakov, A., Kulanthaivelu, R., Bauman, G. S., Ortega, C., Veit‐Haibach, P., & Metser, U. (2022) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-022-00544-3 · Cited by 84
Tilki, D., Schaeffer, E. M., & Evans, C. P. (2016) · European Urology Focus · doi:10.1016/j.euf.2016.11.013 · Cited by 80
Systematic Review of the Volume–Outcome Relationship for Radical Prostatectomy
Leow, J. J. J., Leong, E. K. F., Serrell, E. C., Chang, S. L., Gruen, R. L., Png, K.-S., Beaule, L. T., Trinh, Q., Menon, M., & Sammon, J. D. (2017) · European Urology Focus · doi:10.1016/j.euf.2017.03.008 · Cited by 80
Fred Saad, C., Armstrong, A. J., Thiery-Vuillemin, A., Oya, M., Loredo, E., Procopio, G., Menezes, J. J. D., Girotto, G. C., Arslan, Ç., Mehra, N., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.6_suppl.011 · Cited by 80
Seisen, T., Vetterlein, M. W., Karabon, P., Jindal, T., Sood, A., Nocera, L., Nguyen, P. L., Choueiri, T. K., Trinh, Q., Menon, M., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.08.011 · Cited by 78
Contemporary national trends in prostate cancer risk profile at diagnosis
Fletcher, S. A., von Landenberg, N., Cole, A. P., Gild, P., Choueiri, T. K., Lipsitz, S. R., Trinh, Q., & Kibel, A. S. (2019) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-019-0157-y · Cited by 60
Szymaniak, B. M., Facchini, L. A., Giri, V. N., Antonarakis, E. S., Beer, T. M., Carlo, M. I., Danila, D. C., Dhawan, M., George, D. J., Graff, J. N., et al. (2020) · JCO Oncology Practice · doi:10.1200/op.20.00431 · Cited by 56
Prostate Cancer Foundation Screening Guidelines for Black Men in the United States
Garraway, I. P., Carlsson, S., Nyame, Y. A., Vassy, J. L., Chilov, M., Fleming, M. T., Frencher, S. K., George, D. J., Kibel, A. S., King, S. A., et al. (2024) · NEJM Evidence · doi:10.1056/evidoa2300289 · Cited by 54
HDR brachytherapy as monotherapy for prostate cancer: A systematic review with meta-analysis
Viani, G. A., Arruda, C. V., Pellizzon, A. C. A., & Fendi, L. I. D. (2021) · Brachytherapy · doi:10.1016/j.brachy.2020.10.009 · Cited by 37
Cited by
Cancer treatment and survivorship statistics, 2025
Wagle, N. S., Nogueira, L., Devasia, T. P., Mariotto, A. B., Yabroff, K. R., Islami, F., Jemal, A., Alteri, R., Ganz, P. A., & Siegel, R. L. (2025) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.70011 · Cited by 261
Metadata
- Authors
- Raychaudhuri, R., Lin, D. W., & Montgomery, R. B.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2025-04-22
- Volume
- 333
- Issue
- 16
- Pages
- 1433
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W4408290248
- Cited by
- 355
- References
- 97
- FWCI
- 211.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.